SLS SELLAS Life Sciences Group Inc

$SLS The single biggest bullish takeaway from SLS right now may be what management didn’t do: tap the ATM. Despite having a $150M ATM available, SELLAS appears to have made it through Q3 without issuing shares under it. That matters. Management had access to a substantial source of capital and, based on the disclosures, chose not to dilute shareholders ahead of key clinical catalysts. With $134.7M in cash at quarter-end, there was apparently no need to lean on the ATM simply because the share price provided an opportunity. For me, that is one of the strongest signals in today’s update. A biotech with a strong balance sheet, major catalysts approaching, and an untouched ATM is in a very different position from one that is dependent on the market for near-term funding. No ATM tap = no incremental ATM dilution in Q3. That may be the single most bullish piece of the update that the market is overlooking.

$SLS Management cleared the Q3 ER deck after-hours so the standalone T1 halt gets full spotlight—and look at the two massive clues buried in the PR: 1. REGAL topline officially narrowed to "REPORT THIS MONTH" (only 11 trading days left in Nov, starting with Friday pre-market!). 2. Q3 R&D jumped +67% specifically for manufacturing & regulatory consulting in preparation for a GPS BLA filing! $134.7M cash on hand, zero dilution risk, 57.1M shorts trapped. Steady lah! A November To Remember.

$SLS fudsters - why is the company spending $4.3 million in incremental manufacturing and regulatory consulting expenses tied to preparing for a potential GPS BLA if they think it’s going to fail? I won’t get an answer because I’ve blocked them all

$SLS NO ATM USE REGAL TOPLINE CONFIRMED TO RELEASE THIS NOVEMBER Next week it is. See you there ladies and gentlemen.

$SLS From “imminent” to “this month”, what a journey it’s been. Can’t believe we are almost to the finish line. Massive love and respect to all you longs that chose to participate in something so special and meaningful. Our day is near💪🏻🙏🏻

$SLS if HR under .35 is there any way we don’t run at least 500%? 1000%? At that point we know we have an absolute home run treatment so either we’re gonna get Rich commercializing it or someone will come knocking for many many billions. 

$SLS Going to have best month in my investment period if SLS shows superb REGAL data readout and $CAPR gets Deramiocel approved 🥹🤩

$SLS whoever does not believe that Angelos already has a very very very good idea on what the results are but just awaiting confirmation are very naïve. They know immediately the breakdown of GPS vs BAT patients they also I am sure have spoken numerous time directly to all the trial site managers, and probably the top KOL people at the top hospitals in the world. 

$SLS Stergiou literally spelled it out in plain English+67% more on R&D specifically for GPS BLA manufacturing & FDA regulatory prep while narrowing topline to "REPORT THIS MONTH"… and people still blur! Ha!

$SLS Cash Position: As of September 30, 2026, cash and cash equivalents totaled approximately $134.7 million

$SLS wow.... plemnty of cash, warrants mostly exercised, no ATM usage, positive results, Topline this month...... not to mention 600sqft booth at ASH in December! so very

$SLS Every bear that falsely accused them of using the ATM, here is where you can apologize and admit you have no idea what you are talking about.

$SLS short pressure appears to be increasing. The displayed borrow fee rose from 5.53% yesterday to 9.75% today, an increase of approximately 76% in one session. Nasdaq also reports 57,126,298 shares sold short as of October 30, up more than 3.3 million shares from October 15. That does not prove a squeeze has begun, and a higher borrow rate alone cannot guarantee one. It does, however, indicate that borrowing shares has become materially more expensive while an unusually large short position remains outstanding. The timing is notable. REGAL has reached its 80th event, final analysis is underway, and several potentially significant catalysts remain ahead. If REGAL topline is favorable, a large number of short sellers could be attempting to reduce exposure as new demand enters the market. Shorts have continued carrying substantial risk into a narrowing catalyst window. The borrow market now appears to be repricing that risk. #REGAL #ShortInterest #Biotech

$SLS If I was the CEO, not very confident, and sitting on bad news, I would probably keep my mouth shut and tap that ATM. I certainly would not be showing up on Fox & Friends, nor frequently posting on Linked In, nor would I rent one of the largest spaces at ASH. Just my 2¢.

$SLS with this PR a short squeeze just got confirmed: 10 full trading days left in November 9.36 Days to Cover 56.66M shares short (28.17% of float) Q3 10-Q & PR: "expect to announce the preliminary topline primary endpoint results... in November 2026" Shorts mathematically ran out of trading days to unwind before the T1 halt drops. With $134.7M cash, $0 ATM used, and BlackRock + State Street and others locking up the biggest chunck of the company, 56M+ short shares are trapped in a tightly held float. When that T1 halt hits, the exit door will not fit.

$SLS Increase of manufacturing cost...so you're telling me they needed to keep making more so they had enough for the patients that were staying alive. No need to make more if BAT was living longer

$SLS Sterg wouldn't have changed the wording from "this month" to anything else even if he knew it was coming very soon. I expect topline by end of next week💪

$SLS Announcement SELLAS issued a meaningful REGAL timing update today, November 12, 2026. Confirmed today SELLAS officially narrowed its expected timing for the Phase 3 REGAL topline primary-endpoint results from “Q4 2026” to “this month,” meaning November 2026.

$SLS Passing on a $180M capital raise at $13–$15 shows management's confidence. They expect significant upside.

$SLS TLDR: - At least 10~12 quarters worth of cash runway (137M cash) - Only 7.8M warrants remaining - 237M total share after warrants and RSUs - Did not use any of the ATM with TD Cowen - GPS topline data expected in November (this month) - SLS009 result expected at ASH 2026 in december Looking very good!